Aurealis Therapeutics novel chronic wound treatment to be presented at the 4th Experts Meeting on Microbiome & Skin Health and Disease 2020
Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for Tuesday, December 15th, 2020 at 14:30 CET. More […]
Aurealis Therapeutics to present at the European Wound Management Association (EWMA) Congress 2018
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company’s progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at the European Wound Management Association (EWMA) Congress in Krakow, Poland […]
Aurealis Therapeutics to attend the Swiss Biotech Day 2018
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company’s progress at the Swiss Biotech Day in Basel on May 3rd 2018. The Swiss Biotech Day has long become the standard annual get-together […]
Aurealis Therapeutics to present at the 11th Annual European Life Sciences CEO Forum & Exhibition
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on February 26-27th 2018. The presentation is scheduled for Monday, February […]
Aurealis Therapeutics to present at Swiss Nordic Bio 2018
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018. The presentation is scheduled for: Time: Thursday, February 8th 2018 […]
